Certara introduced its new AI‑powered Quantitative Systems Pharmacology (QSP) platform, Certara IQ, on October 30, 2025. The platform integrates generative AI, a repository of pre‑built models, and a high‑performance simulation engine to accelerate QSP workflows.
Certara IQ addresses long‑standing barriers to QSP adoption, including limited model reuse, lengthy simulation times, complex coding environments, and lack of standardization. The platform offers a no‑code interface, automated model building, and reproducible workflows that can reduce simulation cycles from weeks to days.
The launch expands Certara’s product portfolio beyond its core Simcyp and Phoenix offerings. By adding AI‑driven QSP capabilities, the company aims to capture a larger share of the projected $1.27 billion biosimulation market expected by 2033 and to reinforce its leadership in model‑informed drug development.
In its Q3 2023 financial results, Certara reported revenue of $85.6 million, a 1 % increase over the same period in 2022. The company’s software business grew 9 % year‑over‑year in Q2 2023, driven by strong demand for its simulation tools, while the services segment experienced modest growth amid cautious spending by smaller biotech customers.
CEO William F. Feehery said the launch of Certara IQ represents “the next step in making biosimulation a foundational capability across the entire drug discovery and development value chain.” He added that the platform’s ability to democratize QSP and accelerate simulations will help clients reduce development timelines and risk.
Certara’s broader mission is to transform drug discovery through predictive simulation, data‑driven modeling, and AI. The company notes that its customers have contributed to 90 % or more of all novel drug approvals by the FDA from 2014 to 2024.
The QSP market is projected to reach $1.27 billion by 2033, growing at a CAGR of 13.2 %. QSP‑based FDA submissions have nearly doubled every 1.4 years since 2013, underscoring the growing importance of biosimulation in drug development.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.